If you have a loved one living with Alzheimer's disease, winter can be a difficult season to navigate. Here are some ways to ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Stay updated on the latest potential FDA drug approvals in 2025, including an expanded label for Ozempic and new, nonopioid painkillers.

Independence Blue Cross has instituted an 18-month benefit exclusion on certain drugs that receive accelerated approval from ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

For Floridians, 2024 was a year of weight loss and emerging revelations about anti-obesity medications.

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

The explosive rise of GLP-1 drugs like Ozempic has brought an accompanying challenge: logistics too knotty for a single ...